Diamond: immunohistochemistry versus sequencing in EGFR analysis of lung adenocarcinomas

Aims Identification of epidermal growth factor receptor (EGFR) mutations in lung adenocarcinomas is the single most important predictor of clinical response and outcome using EGFR tyrosine kinase inhibitors (TKIs). EGFR E746-A750del and L858R mutations are the most common gene alterations, also predicting the best clinical response to TKIs. We evaluated the accuracy of EGFR mutation-specific antibodies in a large cohort of lung adenocarcinomas, with different molecular settings and types of tissue samples. Methods 300 lung adenocarcinomas diagnosed on cytology (48 cell blocks), biopsy (157 cases) and surgical resections (95 cases) were selected. All cases were investigated for EGFR by sequencing and two mutation-specific antibodies (clone 6B6 for E746-A750del; clone 43B2 for L858R) were tested using an automated immunostainer. Discordant results were investigated by next-generation sequencing (NGS). Results Overall sensitivity and specificity of mutant-specific antibodies were 58.6% and 98.0%, respectively, and they increased up to 84% and 100% if only tumours harbouring E746-A750del were considered. In 13 discordant cases, NGS confirmed immunohistochemistry results in eight samples. Conclusions The EGFR mutation-specific antibodies have a fair/good sensitivity and good/high specificity in identifying classic mutations, but they cannot replace molecular tests. The antibodies work equally well on biopsies and cell blocks, possibly permitting a rapid screening in cases with poor material.

[1]  K. Tsuta,et al.  Novel use for an EGFR mutation‐specific antibody in discriminating lung adenocarcinoma from reactive pneumocyte hyperplasia , 2015, Histopathology.

[2]  D. Kim,et al.  Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Wei Sun,et al.  Immunohistochemistry with a novel mutation-specific monoclonal antibody as a screening tool for the EGFR L858R mutational status in primary lung adenocarcinoma , 2015, Tumor Biology.

[4]  Yi-long Wu,et al.  Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  G. Rossi,et al.  Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells. , 2014, Lung cancer.

[6]  Mari Mino-Kenudson,et al.  Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cance , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  N. Pavlakis,et al.  EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer , 2014, Pathology.

[8]  Yuh-Min Chen,et al.  Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma , 2014, PloS one.

[9]  Lihua Zhang,et al.  A comparison of ARMS and mutation specific IHC for common activating EGFR mutations analysis in small biopsy and cytology specimens of advanced non small cell lung cancer. , 2014, International journal of clinical and experimental pathology.

[10]  D. Costa,et al.  Management and future directions in non-small cell lung cancer with known activating mutations. , 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[11]  M. Tsao,et al.  Epidermal growth factor receptor mutation‐specific immunohistochemical antibodies in lung adenocarcinoma , 2014, Histopathology.

[12]  B. Skov,et al.  High specificity but low sensitivity of mutation-specific antibodies against EGFR mutations in non-small-cell lung cancer , 2014, Modern Pathology.

[13]  Yan-Ze Jin,et al.  Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry. , 2014, Lung cancer.

[14]  G. Tallini,et al.  Next Generation Sequencing Improves the Accuracy of KRAS Mutation Analysis in Endoscopic Ultrasound Fine Needle Aspiration Pancreatic Lesions , 2014, PloS one.

[15]  Yi-long Wu,et al.  Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[16]  Dario de Biase,et al.  Next-Generation Sequencing of Lung Cancer EGFR Exons 18-21 Allows Effective Molecular Diagnosis of Small Routine Samples (Cytology and Biopsy) , 2013, PloS one.

[17]  I. Wistuba,et al.  The evolving genomic classification of lung cancer , 2013, The Journal of pathology.

[18]  T. Chou,et al.  Molecular diagnostic algorithm for epidermal growth factor receptor mutation detection in Asian lung adenocarcinomas: Comprehensive analyses of 445 Taiwanese patients with immunohistochemistry, PCR‐direct sequencing and Scorpion/ARMS methods , 2013, Respirology.

[19]  M. Fiorentino,et al.  454 next generation-sequencing outperforms allele-specific PCR, Sanger sequencing, and pyrosequencing for routine KRAS mutation analysis of formalin-fixed, paraffin-embedded samples , 2013, OncoTargets and therapy.

[20]  Hao-dong Xu,et al.  Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples. , 2013, Human pathology.

[21]  Robert Brian Jenkins,et al.  Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  S. O'toole,et al.  EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma , 2013, Journal of Clinical Pathology.

[23]  Yan-Ze Jin,et al.  High concordance of EGFR mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas , 2013, Cancer cytopathology.

[24]  M. Ladanyi,et al.  Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma , 2013, Modern Pathology.

[25]  E. Wang,et al.  Ascertaining an Appropriate Diagnostic Algorithm Using EGFR Mutation-Specific Antibodies to Detect EGFR Status in Non-Small-Cell Lung Cancer , 2013, PloS one.

[26]  Qiong Lu,et al.  A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non–Small-Cell Lung Cancer , 2013, PloS one.

[27]  P. Rothberg,et al.  Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies , 2013, Diagnostic Pathology.

[28]  Marc Ladanyi,et al.  EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics , 2013, Molecular Cancer Therapeutics.

[29]  Kunihiko Kobayashi,et al.  Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC) , 2013, Targeted Oncology.

[30]  Gillian Ellison,et al.  EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples , 2012, Journal of Clinical Pathology.

[31]  M. Zakowski,et al.  Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma. , 2012, Lung cancer.

[32]  A. Ardizzoni,et al.  EGFR Mutation-specific Antibodies in Pulmonary Adenocarcinoma: A Comparison With DNA Direct Sequencing , 2012, Applied immunohistochemistry & molecular morphology : AIMM.

[33]  P. Validire,et al.  Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  Yih-Leong Chang,et al.  Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[35]  F. López-Ríos,et al.  Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) , 2012, Clinical and Translational Oncology.

[36]  L. Bubendorf,et al.  The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. , 2012, Lung cancer.

[37]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[38]  Gwan Ho Lee,et al.  Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. , 2012, Lung cancer.

[39]  Kazutaka Nakashima,et al.  Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. , 2011, Lung cancer.

[40]  Yih-Leong Chang,et al.  Including Total EGFR Staining in Scoring Improves EGFR Mutations Detection by Mutation-Specific Antibodies and EGFR TKIs Response Prediction , 2011, PloS one.

[41]  Masahiro Fukuoka,et al.  Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Kenji Suzuki,et al.  The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma. , 2011, Lung cancer.

[43]  J. Shih,et al.  Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer , 2011, Clinical Cancer Research.

[44]  A. Iafrate,et al.  Genetically informed lung cancer medicine , 2011, The Journal of pathology.

[45]  Miguel Angel Molina,et al.  Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer , 2010, Journal of Translational Medicine.

[46]  M. Takagi,et al.  Immunohistochemical detection of mutated epidermal growth factor receptors in pulmonary adenocarcinoma. , 2010, Anticancer research.

[47]  T. Ohira,et al.  Novel Epidermal Growth Factor Receptor Mutation-Specific Antibodies for Non-small Cell Lung Cancer: Immunohistochemistry as a Possible Screening Method for Epidermal Growth Factor Receptor Mutations , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[48]  P. Hofman,et al.  Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma , 2010, Virchows Archiv.

[49]  Y. Yatabe,et al.  Immunohistochemical Detection of EGFR Mutation Using Mutation-Specific Antibodies in Lung Cancer , 2010, Clinical Cancer Research.

[50]  T. Mitsudomi,et al.  Molecular Diagnosis of Activating EGFR Mutations in Non–Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis , 2010, Clinical Cancer Research.

[51]  M. Ladanyi,et al.  Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. , 2010, The Journal of molecular diagnostics : JMD.

[52]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[53]  M. Loda,et al.  Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer , 2009, Clinical Cancer Research.

[54]  W. Pao,et al.  Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Kikuya Kato,et al.  Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib , 2008, Cancer science.

[56]  G. Rossi,et al.  A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis. , 2008, American journal of clinical pathology.

[57]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[58]  Quynh-Thu Le,et al.  Non-small cell lung cancer: Clinical practice guidelines in oncology , 2006 .

[59]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[60]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.